10x Genomics, Inc. (TXG)

Market Cap	5.14B
Revenue (ttm)	590.98M
Net Income (ttm)	-223.36M
Shares Out	118.21M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	196.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	793,862
Open	43.50
Previous Close	43.32
Day's Range	42.67 - 43.70
52-Week Range	31.28 - 63.57
Beta	1.84
Analysts	Buy
Price Target	58.60 (+34.65%)
Earnings Date	Nov 2, 2023

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for me...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,243
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG

Financial Performance

In 2022, 10x Genomics's revenue was $516.41 million, an increase of 5.28% compared to the previous year's $490.49 million. Losses were -$166.00 million, 185.1% more than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $58.6, which is an increase of 34.65% from the latest price.

Price Target

$58.6

(34.65% upside)

Analyst Consensus: Buy